Ayşe Ünal

Dr. Ayşe Ünal

Biochemistry, Ege University, İzmir, Turkey (Türkiye)
orcid

Research Focus & Metrics

Representative Publications

View All Publications
1 October 2021 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
GAGüliz Ak
Güliz Ak
AÜAyşe Ünal
Ayşe Ünal
TKTuğba Karakayalı
Tuğba Karakayalı
BÖBuket Özel
Buket Özel
NGNur Selvi Günel
Nur Selvi Günel
ŞŞŞenay Hamarat Şanlıer
Şenay Hamarat Şanlıer

1 March 2019 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SSSenay Hamarat Sanlier
Senay Hamarat Sanlier
GAGüliz Ak
Güliz Ak
HYHabibe Yılmaz
Habibe Yılmaz
AÜAyşe Ünal
Ayşe Ünal
ÜBÜmmühan Fulden Bozkaya
Ümmühan Fulden Bozkaya
GTGülbeyaz Yıldız Türkyılmaz
Gülbeyaz Yıldız Türkyılmaz

1 January 2020 in Journal of Basic and Clinical Health Sciences
Verified
Journal Article
Closed access
AÜAyşe Ünal
Ayşe Ünal
GAGüliz Ak
Güliz Ak
SŞSenay Hamarat Şanlıer
Senay Hamarat Şanlıer

8 December 2025 in European Journal of Therapeutics
Verified
Journal Article
Open access
PDF file
AÜAyşe Ünal
Ayşe Ünal
SSSenay Hamarat Sanlier
Senay Hamarat Sanlier
Objective: Albumin, a biodegradable, biocompatible, and non-toxic plasma protein, is widely used as a nanocarrier in drug delivery systems. Pemetrexed, a potent thymidylate synthase inhibitor for non-small cell lung cancer (NSCLC), is limited by severe systemic side effects. Embedding magnetite within albumin carriers enables external-field guidance (magnetic targeting), which enhances tumor accumulation while reducing off-target exposure. Additionally, employing genipin as a natural, biodegradable, and low-cytotoxicity crosslinker stabilizes the albumin matrix while eliminating the use of toxic aldehyde-based agents.This study introduces a genipin-crosslinked, magnetically targetable albumin nanoparticle platform for enhanced and controlled delivery of pemetrexed to lung cancer cells. Unlike previous pemetrexed–albumin systems, this dual design—combining genipin crosslinking with magnetite-mediated targeting—offers improved structural stability, biocompatibility, and site-specific delivery potential Methods: Bovine serum albumin (BSA) nanoparticles were prepared via desolvation using genipin as the crosslinker and magnetite for magnetic responsiveness. Key formulation parameters—BSA concentration, genipin content, magnetite ratio, reaction time, and drug loading—were systematically optimized. Drug release from free pemetrexed and nanoparticle formulations was evaluated at pH 7.4 and 5.5. Nanoparticles were characterized by SEM, FTIR, and zeta potential; cytotoxic efficacy was assessed in A549-luc-C8 and CRL-5807 lung cancer cells. Results: The nanoparticle yielded spherical, negatively charged nanoparticles with sustained, pH-responsive release. In vitro, the genipin-crosslinked, magnetite-containing nanoparticles demonstrated improved antitumor efficacy versus free drug. Conclusion: Magnetite provides a handle for external magnetic guidance, supporting targeted delivery, while genipin crosslinking minimizes residual crosslinker toxicity and stabilizes the carrier network. Together, genipin crosslinking + magnetic targeting define the novelty and translational potential of this system, with the prospect of reducing systemic exposure via controlled, site-directed delivery.

2 October 2025 in Journal of Liposome Research
Verified
Journal Article
Closed access
GAGüliz Ak
Güliz Ak
HYHabibe Yılmaz
Habibe Yılmaz
ÜAÜmmühan Fulden Aydın
Ümmühan Fulden Aydın
AÜAyşe Ünal
Ayşe Ünal
ÖTÖzge Sarı Turgut
Özge Sarı Turgut
ŞŞŞenay Hamarat Şanlıer
Şenay Hamarat Şanlıer
The high rate of lung cancer and related deaths necessitated new treatment strategies. This study aimed at in vitro, in vivo, and ex vivo evaluation of magnetic field sensitive, ultrasound-mediated, and pemetrexed and pazopanib containing nanobubble (NB) destruction to provide dual drug therapy against non-small cell lung cancer. For this purpose, cytotoxicity analysis (CRL-5807, CRL-5826, A549-Luc-C8), biocompatibility experiments including hemocompatibility, uptake by macrophages, and binding to serum proteins, acute and long-term toxicity analyses, in vivo therapeutic efficacy experiments, pharmacokinetic analyses, histochemistry, and immunohistochemistry experiments were performed on NBs. The IC50 value of NB-400 against A549-Luc-C8 was found to be 31.4 ± 1.6 μg/mL and 34.9 ± 1.2 μg/mL with and without ultrasound application for 72 h, respectively. 30.8% of NB-400 was phagocytosed by macrophage cells and was non-hemolytic. It was determined that NB-800 (prepared for inhaler administration) and NB-400 did not cause acute or long-term toxic effects and reduced tumor size and/or disappeared after treatment, but carrier-free dual drugs did not give a therapeutic response also based on immunohistochemical analyses. It can be said that the emerging intravenous and inhaled delivery systems can be potential therapeutics that can be used in the treatment of non-small cell lung cancer with superior properties such as magnetic targeting and ultrasound sensitivity.

23 September 2026 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
AÜAyşe Ünal
Ayşe Ünal
GAGüliz Ak
Güliz Ak
HYHabibe Yılmaz
Habibe Yılmaz
TKTuğba Karakayalı Kavruk
Tuğba Karakayalı Kavruk
AEAyça Erek
Ayça Erek
SSSenay Hamarat Sanlier
Senay Hamarat Sanlier